Biotech Values

[mcbio]

Does anyone here care to proffer an opinion on ATN-103? Is my reading of Ablynx’s PR in #msg-63230818 unduly skeptical? T.i.a.

I agree with your skeptical take, particularly as it relates to the following language from the PR that you bolded: "Pfizer have now confirmed that clinical proof-of-concept has been achieved and they are now engaged in a full technical, clinical and commercial evaluation to determine whether and how to take ATN-103 forward."

Ablynx doesn't exactly sound too confident in the latter part of that quote do they? Now that PoC has been achieved, PFE still has to make a determination whether or not they want to take the program forward? That's probably not surprising is it given that this program will have to compete with all of the TNF-alpha biologic drugs on the market, the oral drug(s) possibly coming to market soon from the likes of PFE, AZN/RIGL, ABT/INCY, along with the threat a little further down the road from generic biologics? I wonder even how differentiated this Ablynx drug is from all of this competition in terms of efficacy/safety, if at all.